Larimar Therapeutics, Inc. (LRMR) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 2.44 |
| Open | 2.47 |
| Day High | 2.54 |
| Day Low | 2.39 |
| 52-Week High | 6.42 |
| 52-Week Low | 1.92 |
| Volume | 1.51M |
| Average Volume | 1.32M |
| Market Cap | 251.4M |
| PE | -1.24 |
| EPS | -1.95 |
| Moving Average 50 Days | 3.47 |
| Moving Average 200 Days | 3.84 |
| Change | -0.02 |
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
GlobeNewswire Inc.
Mar 04, 2026 9:05 PM GMT
BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
GlobeNewswire Inc.
Feb 26, 2026 1:59 AM GMT
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its upsized
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
GlobeNewswire Inc.
Feb 25, 2026 9:01 PM GMT
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an u